870221-30-0 Usage
Chemical structure
A 1,3,2-dioxaborolane core with four methyl groups and a substituted phenyl group.
Potential applications
Chemical synthesis and material science, particularly in the development of organic electroluminescent materials.
Nitro group
Provides a site for further chemical modifications, making the compound a valuable building block for the synthesis of more complex molecules with specific properties.
Boron-containing core
Participates in various organic reactions, making it a versatile and useful reagent in organic chemistry.
Functional groups
Contains a nitro group (-NO2) and a phenoxy group (-OC6H4-O-) attached to the phenyl ring.
Molecular weight
Approximately 323.16 g/mol
Solubility
Soluble in organic solvents such as dichloromethane, tetrahydrofuran, and dimethyl sulfoxide (DMSO).
Reactivity
Can undergo various organic reactions, such as nucleophilic substitution, electrophilic aromatic substitution, and reduction of the nitro group.
Check Digit Verification of cas no
The CAS Registry Mumber 870221-30-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,0,2,2 and 1 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 870221-30:
(8*8)+(7*7)+(6*0)+(5*2)+(4*2)+(3*1)+(2*3)+(1*0)=140
140 % 10 = 0
So 870221-30-0 is a valid CAS Registry Number.
870221-30-0Relevant articles and documents
PROTEIN KINASE MODULATORS AND METHOD OF USE
-
Page/Page column 128, (2010/02/14)
The present invention relates to chemical compounds having a general formula I wherein A, B, D, E, G, H1-5 and R1-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other poliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of protein kinases.
